Oligo Medic strives to provide innovations that enable less invasive surgical treatments, always simplifying the surgeon’s workflow

Obtained license from TGA for JointRep® in Australia.

2019

Obtained license from Health Canada for JointRep®.

2018

Preliminary steps taken toward procedures with FDA for market approval in the US.

2018

Gaining market penetration in Europe, ANZ regions, Middle East, South East Asia, and Latin America

2018

Very favorable results on clinical trial published in Journal of Clinical Orthopedics and Trauma.

2018

Other clinical trials on different indications are planned and will be disclosed when protocols are defined.

2017

Initiated European controlled clinical trial: 69 patients and comparing microfracture to microfracture & JointRep®.

2015

Initial experimentation with JointRep® and microfracture. Results are highly favorable with fast pain relief, accelerated recovery time, and nice cartilage regrowth.

2014

Structured OligoMedic for distribution partnership and initiated case studies and post market evaluation.

2012Manufacturing, packaging, and shipping processes defined. Obtained CE mark in October.

2013

Follow up case series on Health Canada SAP.

2011

Creation of Oligo Medic Inc. Development of technology platform. Bench testing and pre-clinical characterization. Initiated Health Canada Special Access Program ("SAP"). Successful first-in-man JointRep® operation.

2010

© 2019 OLIGO MEDIC. All Rights Reserved. Contact